Drug class
CD20-directed CD3 T-cell-engaging bispecific monoclonal antibody; antineoplastic biologic
Mechanism of action
Binds CD20 on B cells and CD3 on T cells, bringing T cells into proximity with malignant B cells and inducing T-cell activation and B-cell lysis.
General use cases
- Treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy under the US product indication; EU product indications and line-of-therapy requirements should be checked separately
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
